Boonen, S., Kaufman, J.-M., Lippuner, K., Zanchetta, J., Langdahl, B., Rizzoli, R., et al. (2012) Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. The New England Journal of Medicine, 367, 1714-1732.
https://doi.org/10.1056/NEJMoa1204061

has been cited by the following article:

• TITLE: Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis

  AUTHORS: IsraaIsraa Ahmed Radwan, Nahed Sedky Korany, Bassant Adel Ezzat

  KEYWORDS: Bisphosphonates, Alendronate, Zoledronate, Postmenopausal Osteoporosis

  JOURNAL NAME: Case Reports in Clinical Medicine, Vol.7 No.5, May 10, 2018

  ABSTRACT: Bisphosphonates are among the most frequently used antiresorptive drugs for the management of postmenopausal osteoporosis. We review here two of the commonly used bisphosphonates zoledronate and alendronate.